HUTCHMED (China) Beheer

Beheer criteriumcontroles 4/4

De CEO HUTCHMED (China) is Wei-Guo Su, benoemd in Jan2012, heeft een ambtstermijn van 12.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.45M, bestaande uit 32.5% salaris en 67.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.49% van de aandelen van het bedrijf, ter waarde € 13.85M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.5 jaar en 7.7 jaar.

Belangrijke informatie

Wei-Guo Su

Algemeen directeur

US$2.5m

Totale compensatie

Percentage CEO-salaris	32.5%
Dienstverband CEO	12.8yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	6.5yrs
Gemiddelde ambtstermijn bestuur	7.7yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Wei-Guo Su's beloning veranderd ten opzichte van HUTCHMED (China)'s winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$42m
Mar 31 2024	n/a	n/a	US$29m
Dec 31 2023	US$2m	US$798k	US$101m
Sep 30 2023	n/a	n/a	US$36m
Jun 30 2023	n/a	n/a	-US$29m
Mar 31 2023	n/a	n/a	-US$195m
Dec 31 2022	US$4m	US$700k	-US$361m
Sep 30 2022	n/a	n/a	-US$308m
Jun 30 2022	n/a	n/a	-US$255m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$3m	US$395k	-US$195m
Sep 30 2021	n/a	n/a	-US$187m
Jun 30 2021	n/a	n/a	-US$178m
Mar 31 2021	n/a	n/a	-US$151m
Dec 31 2020	US$1m	US$346k	-US$126m
Sep 30 2020	n/a	n/a	-US$117m
Jun 30 2020	n/a	n/a	-US$110m
Mar 31 2020	n/a	n/a	-US$102m
Dec 31 2019	US$1m	US$274k	-US$106m
Sep 30 2019	n/a	n/a	-US$93m
Jun 30 2019	n/a	n/a	-US$87m
Mar 31 2019	n/a	n/a	-US$83m
Dec 31 2018	US$1m	US$273k	-US$75m
Sep 30 2018	n/a	n/a	-US$72m
Jun 30 2018	n/a	n/a	-US$61m
Mar 31 2018	n/a	n/a	-US$39m
Dec 31 2017	US$2m	US$310k	-US$27m

Compensatie versus markt: De totale vergoeding ($USD 2.45M ) Wei-Guo } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 1.92M ).

Compensatie versus inkomsten: De vergoeding van Wei-Guo is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Wei-Guo Su (66 yo)

12.8yrs

Tenure

US$2,451,164

Compensatie

Dr. Wei-Guo Su, B.Sc., Ph D., has been the Chief Executive Officer of HUTCHMED (China) Limited since March 04, 2022. Dr. Su has been the Chief Scientific Officer and Executive Vice President of HUTCHMED (C...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	12.8yrs	US$2.45m	0.49% € 13.8m
Chig Fung Cheng	CFO & Executive Director	16.3yrs	US$962.15k	0.18% € 5.1m
Edith Shih	Company Secretary & Non-Executive Director	18.8yrs	geen gegevens	geen gegevens
Yiling Cui	Executive VP & Head of Operations	less than a year	geen gegevens	geen gegevens
David Ng	Head of Investor Relations & Capital Strategies	no data	geen gegevens	geen gegevens
Charles George Rupert Nixon	Group General Counsel	9.5yrs	geen gegevens	geen gegevens
Kin Hung Lee	Senior Vice President of Corporate Management & Communications	1.8yrs	geen gegevens	geen gegevens
Selina Zhang	Senior Vice President of Global Human Resources	2.8yrs	geen gegevens	geen gegevens
Qingmei Wang	Senior Vice President of Business Development & Strategic Alliances	no data	geen gegevens	geen gegevens
Zhenping Wu	Executive Vice President of Pharmaceutical Science & Manufacturing	12.8yrs	geen gegevens	geen gegevens
Thomas Fu	Senior Vice President of Global Quality	3.6yrs	geen gegevens	geen gegevens
Ming Shi	Executive VP	2.3yrs	geen gegevens	geen gegevens

6.5yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van H7T2 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Wei-Guo Su	CEO, Chief Scientific Officer & Executive Director	7.7yrs	US$2.45m	0.49% € 13.8m
Chig Fung Cheng	CFO & Executive Director	13.8yrs	US$962.15k	0.18% € 5.1m
Edith Shih	Company Secretary & Non-Executive Director	18.8yrs	geen gegevens	geen gegevens
Dan Eldar	Non-Executive Chairman	8.3yrs	geen gegevens	0.013% € 362.5k
Ling Yang	Non-Executive Director	1.3yrs	geen gegevens	geen gegevens
Graeme Allan Jack	Independent Non-Executive Director	7.7yrs	US$111.00k	0.0053% € 151.0k
Paul Rutherford Carter	Senior Independent Non-Executive Director	7.8yrs	US$117.00k	0.0087% € 244.9k
Shu Kam Mok	Independent Non-Executive Director	7.1yrs	US$114.86k	0.011% € 316.4k
Renu Bhatia	Independent Non-Executive Director	less than a year	geen gegevens	geen gegevens
Chaohong Hu	Independent Non-Executive Director	no data	geen gegevens	geen gegevens

7.7yrs

Gemiddelde duur

64.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van H7T2 wordt beschouwd als ervaren (gemiddelde ambtstermijn 7.7 jaar).

HUTCHMED (China) Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Recent updates

HUTCHMED (China) Limited Announces Appointment of Chaohong Hu as Independent Non-Executive Director and Member of Technical Committee, Effective November 21, 2024

HUTCHMED (China) Limited Announces Positive High-Level Results from the SAVANNAH Phase II Trial

Hutchmed (China) Limited Highlights Clinical Data to Be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer

HUTCHMED Provides Update on Fruquintinib for Second-Line Gastric Cancer in China

First half 2024 earnings released: EPS: US$0.03 (vs US$0.20 in 1H 2023)

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

HUTCHMED (China) Limited to Report First Half, 2024 Results on Jul 31, 2024

Hutchmed Highlights Publication of Phase Iii Eslim-01 Results in the Lancet Haematology

HUTCHMED (China) Limited Initiates Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China

HUTCHMED (China) Limited Highlights Publication of Phase III FRUTIGA Results in Nature Medicine

HUTCHMED (China) Limited Highlights Presentations of New and Updated Data from Several Studies of Compounds Discovered by HUTCHMED At the Upcoming American Society of Clinical Oncology

HUTCHMED (China) Limited Announces Executive Changes

HUTCHMED (China) Limited Initiates the RAPMichael Registrational Phase III Trial of HMPL-306 for Patients with IDH1- and/or IDH2-Mutated Relapsed/Refractory Acute Myeloid Leukemia in China

HUTCHMED (China) Limited Initiates Phase II/III Trial of the Combination of Surufatinib and Camrelizumab for Treatment-Naive Pancreatic Ductal Adenocarcinoma in Collaboration with Hengrui

Investor sentiment improves as stock rises 15%

HUTCHMED (China) Limited Appoints Dr. Renu Bhatia as an Independent Non-Executive Director and a Member of Technical Committee, Effective May 13, 2024

Investor sentiment improves as stock rises 19%

New major risk - Share price stability

HUTCHMED (China) Limited, Annual General Meeting, May 10, 2024

HUTCHMED (China) Limited Highlights Data to be Presented at AACR Congress 2024

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status

HUTCHMED (China) Limited Announces Savolitinib sNDA Accepted in China for Treatment-Naive or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC

Hutchmed Initiates Registration Stage of the Eslim-02 Phase Ii/Iii Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Investor sentiment improves as stock rises 22%

HUTCHMED (China) Limited Provides Revenue Guidance for the Year 2024

Full year 2023 earnings released: EPS: US$0.12 (vs US$0.43 loss in FY 2022)

Hutchmed (China) Limited Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer At Asco Plenary Series Session

HUTCHMED (China) Limited to Report Fiscal Year 2023 Results on Feb 28, 2024

HUTCHMED (China) Limited Receives Elunate® (Fruquintinib) Marketing Approval in Hong Kong for Treatment of Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces NDA Acceptance in China for Sovleplenib for the Treatment of Primary Immune Thrombocytopenia with Priority Review Status

HUTCHMED (China) Limited Completes Enrollment of a Phase II/III Trial of Fruquintinib in Combination with Sintilimab for Advanced Renal Cell Carcinoma in China

Hutchmed (China) Limited Announces First in Human, Open-Label, Dose-Escalation Study of Erk1/2 Inhibitor Hmpl-295 in Patients with Advanced Solid Tumors

HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan

HUTCHMED (China) Limited Announces Presentation of Results from the Phase IIIb Trial of Savolitinib at the 2023 World Conference of Lung Cancer

Hutchmed (China) Limited Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

New minor risk - Shareholder dilution

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HUTCHMED (China) Limited Announces the Sovleplenib Phase III ESLIM-01 Study Met its Primary Endpoint in Primary Immune Thrombocytopenia in China

First half 2023 earnings released: EPS: US$0.20 (vs US$0.19 loss in 1H 2022)

HUTCHMED (China) Limited Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

HUTCHMED (China) Limited Announces Changes to Board of Directors and Technical Committee

Hutchmed (China) Limited Initiates Phase I Study of Its Novel SHP2 Inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HUTCHMED (China) Limited to Report First Half, 2023 Results on Jul 31, 2023

HUTCHMED (China) Limited and Takeda Announce Publication of Phase III FRESCO-2 Results in the Lancet

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

HUTCHMED (China) Limited and Takeda Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

HUTCHMED (China) Limited Announces New and Updated Clinical Data Related to HUTCHMED

HUTCHMED (China) Limited Appoints Solange Peters as Independent Non-Executive Director, Member of the Technical Committee and Member of the Audit Committee

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

CFO & Executive Director recently sold €2.7m worth of stock

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.25 loss in FY 2021)

HUTCHMED (China) Limited to Report Fiscal Year 2022 Results on Feb 28, 2023

HUTCHMED (China) Limited Announces Agreement with NHSA for Inclusion of ORPATHYS in the National Reimbursement Drug List in China

Hutchmed Completes Patient Enrollment of Eslim-01, A Phase Iii Trial of Sovleplenib in Primary Immune Thrombocytopenia in China

HUTCHMED Initiates Rolling Submission of Nda to U.S. Fda for Fruquintinib for the Treatment of Refractory Colorectal Cancer

Less than half of directors are independent

HUTCHMED (China) Limited Announces Positive Topline Result in Fruquintinib Phase III FRUTIGA Study in Second-Line Gastric Cancer in China

Hutchmed (China) Limited Initiates Phase 2/3 Trial of Fruquintinib

Now 20% undervalued after recent price drop

HUTCHMED (China) Limited Initiates Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China

Now 23% undervalued after recent price drop

HUTCHMED (China) Limited Announces Summary Results of the 691-Patient, Multi-Regional Clinical Trial

Inmagene Biopharmaceuticals and HUTCHMED (China) Limited Announce First Participant in Global Phase I Trial of IMG-004

HUTCHMED (China) Limited Announces that Fruquintinib Global Phase III FRESCO-2 Study Has Met Its Primary Endpoint in Metastatic Colorectal Cancer

HUTCHMED (China) Limited Announces Fruquintinib Global Phase III FRESCO-2 Study in Metastatic Colorectal Cancer

First half 2022 earnings released

HUTCHMED (China) Limited Initiates A Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HUTCHMED (China) Limited Initiates Phase I Trial of Anti-CD47 Monoclonal Antibody HMPL-A83 in Patients with Advanced Malignant Neoplasms in China